

PUBLIC NOTICE
Notice is hereby given that 22 shares of SIGNIFY INNOVATIONS INDIA LTD having Reg.office PS ARCADIA CENTRAL, 3A, 3RD FLOOR, 4A, ABANINDRANATH THAKUR SARANI (CAMAC STREET), KOLKATA - 700017, under Folio No. 012528, Distinctive Nos. 56156737 - 56156758, Certificate nos. 12528 for 22 Shares(10 PAID UP), standing in the names of LATE EBRAHIM MOHAMEDALI KASUBHAI, has been lost or mislaid and Claimant DURRAIYA AKBER AHUJA has applied to the company to issue duplicate certificate Any person who has claim in respect of the aforesaid shares should lodge such claim with the Company, at its registered office ,within 15 day from this date, else Company will processed to issue duplicate certificate.

PUBLIC NOTICE
Notice is hereby given that SHARE CERTIFICATE NO. 065/06 bearing distinctive nos. from 321 to 325 of LADY RATAN TOWER CO-OP. HSG. SOC. LTD, situated at Dainik shivner Marg, Worli, Mumbai 400018, in the name of Ashish Anil Tholia has been reported lost/misplaced and application has been made by Ashish Anil Tholia (Owner) to the society for issue of duplicate share certificate.
The society hereby invites claims or objection (in writing) for issuance of duplicate Share Certificate within the Period of 14 days from the publication of this notice, in case of no claims/objections are received during this period the society shall be free to issue the duplicate Share Certificate for Behalf of Lady Ratan Tower Co-op. Hsg. Soc. Ltd.
Place : Mumbai

PUBLIC NOTICE
Notice is hereby given that 22 shares of PHILIPS INDIA LTD having Reg. office 3RD FLOOR, TOWERA, DLF IT PARK, 08 BLOCKAF, MAJOR ARTERIAL ROAD, NEW TOWN (RAJARHAT), KOLKATA- 700156, WEST BENGAL under Folio No. 9010127, Distinctive Nos. 23408798 - 23408799, 43965565 - 43965565, 43965566 - 43965566 & 1495088 - 1495105, Certificate nos.1276, 133171, 133172 & 8013305 for 22 Shares (10 PAID UP), standing in the names of LATE EBRAHIM MOHAMEDALI KASUBHAI, has been lost or mislaid and Claimant DURRAIYA AKBER AHUJA has applied to the company to issue duplicate certificate. Any person who has claim in respect of the aforesaid shares should lodge such claim with the Company, at its registered office ,within 15 day from this date ,else Company will processed to issue duplicate certificate

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON SME PLATFORM OF BSE LIMITED ("BSE SME")



SOBO FILMS HOLDING LIMITED
CIN: U73100MH2012PLC225824

Our Company was originally incorporated as a private limited Company under the Companies Act, 1956 in the name and style of "SOBO Films Holding Private Limited" bearing Corporate Identification Number U73100MH2012PTC225824 dated January 06, 2012, issued by the Registrar of Companies, Mumbai. Subsequently, our Company was converted into public limited Company pursuant to a Special Resolution passed at an Extra-Ordinary General Meeting held on January 10, 2025 and name of our Company was changed to "SOBO Films Holding Limited" and a fresh Certificate of Incorporation dated January 27, 2025 was issued by Registrar of Companies, Mumbai. As on date of the Draft Prospectus, the Corporate Identification Number of our Company is U73100MH2012PLC225824. For further details of incorporation please refer to section titled "*History and Corporate Structure*" beginning on page 178 of the Draft Prospectus.

Registered office: 713, 7th Floor, Crystal Paradise Mall, Dattaji Salvi Road, Off Veera Desai Road, Andheri (West), Mumbai - 400 053, Maharashtra, India;
Tel No.: +91- 9892950013 **Website:** www.sobofilms.com; **E-Mail:** compliance@sobofilms.com
Contact Person: Sakshi Saxena, Company Secretary and Compliance Officer

OUR PROMOTERS: SMRUTI SUSHILKUMAR SHINDE and HARVINDAR SINGH ARORA

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISE) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME")."

THE ISSUE

INITIAL PUBLIC ISSUE* OF UPTO 34,32,000 EQUITY SHARES OF FACE VALUE ₹ 10/- EACH ("EQUITY SHARES") OF SOBO FILMS HOLDING LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ [●] PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ [●] LAKHS (THE "ISSUE"). [●] EQUITY SHARES AGGREGATING TO ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE AGGREGATING TO ₹ [●] LAKHS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [●] % AND [●] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

FOR FURTHER DETAILS, PLEASE REFER THE SECTION TITLED "TERMS OF THE ISSUE" ON PAGE 308 OF THE DRAFT PROSPECTUS. THE PRICE AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE LEAD MANAGER ("LM") AND WILL BE ADVERTISED IN ALL EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND ALL EDITIONS OF [●] (A WIDELY CIRCULATED MARATHI DAILY NEWSPAPER, MARATHI BEING THE REGIONAL LANGUAGE OF MUMBAI, WHERE OUR REGISTERED OFFICE IS LOCATED) AT LEAST TWO (2) WORKING DAYS PRIOR TO THE ISSUE OPENING DATE IN ACCORDANCE WITH BSE THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS"), AND SUCH ADVERTISEMENT SHALL BE MADE AVAILABLE TO BOMBAY STOCK EXCHANGE LIMITED ("BSE") (THE "STOCK EXCHANGE") FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.

In case of any revision in the Price, Issue Period shall be extended for at least three (3) additional Working Days after such revision of the Price, subject to the Issue Period not exceeding a total of ten (10) Working Days. Any revision in the Price, and the Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchange by issuing a press release and also by indicating the change on the websites of the LM and at the terminals of the Syndicate Members, and by intimation to Self-Certified Syndicate Banks ("SCSBs"), the Sponsor Banks and other entities at such addresses as may be applicable. In case of force majeure, banking strike or similar circumstances, the Company may for reasons recorded in writing, extend the Issue Period by at least three (3) additional working days subject to the total Issue Period not exceeding ten (10) Working Days.

The Issue is being made in terms of Rule 19(2)(b)(i) of the Securities Contract (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations, the Issue is being made for at least 25% of the post-Issue paid up Equity Share capital of our Company. The Issue is being made through the Fixed Price process in accordance and compliance with Chapter IX and other applicable provisions of SEBI ICDR Regulations, 2018, wherein a minimum of 50% of the Net Issue is allocated for Individual Investors and the balance shall be offered to individual applicants other than Individual Investors and other investors including corporate bodies or institutions, QIBs and Non-Institutional Applicants. However, if the aggregate demand from the Individual Investors is less than 50%, then the balance Equity Shares in that portion will be made available for allocation to other remaining investors including QIBs and NIs and vice-versa subject to the total Applications being received from them at or above the Issue Price. Additionally, if the Individual Applicants category is entitled to more than fifty per cent on proportionate basis, the Individual Applicants shall be allocated that higher percentage. For further details please refer to the section titled "*Issue Related Information*" beginning on page no. 308 of the Draft Prospectus.

This public announcement is being made in compliance with SEBI ICDR Regulations to inform the public that the Company is proposing, subject to requisite approvals, market conditions and other considerations, an initial public offering of its Equity Shares and has filed the Draft Prospectus dated September 30, 2025 with SME platform of BSE Limited being the Stock Exchange.

Pursuant to SEBI ICDR Regulations, the Draft Prospectus filed with Exchange shall be made public for comments, if any, for a period of at least 21 (twenty one) days from the date of such filing, by hosting it on the websites of the Company at www.sobofilms.com and the LM at www.comfortsecurities.co.in and the Stock Exchange where the Equity Shares are proposed to be listed, i.e. BSE at www.bseindia.com. Our Company hereby invites the public to give their comments on the Draft Prospectus filed with exchange in respect of disclosures made in the Draft Prospectus. The public is requested to send a copy of comments sent to exchange, to the Company Secretary and Compliance Officer of our Company and the LM at their respective addresses mentioned below. All comments must be received by our Company or the LM on or before 5 p.m. on the 21st day from the aforementioned date of filing of the Draft Prospectus.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the exchange, nor does exchange guarantee the accuracy or adequacy of the contents of the Draft Prospectus. Specific attention of the investors is invited to the section titled "*Risk Factors*" on page no. 34 of the Draft Prospectus. Any decision to invest in the Equity Shares described in the Draft Prospectus shall be made after a Prospectus ("Prospectus") has been registered with the ROC, Mumbai. The Equity Shares, when offered through Draft Prospectus, are proposed to be listed on Stock Exchange.

For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "*Capital Structure*" beginning on page 85 of the Draft Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "*Our History and Corporate Structure*" beginning on page 178 of the Draft Prospectus. "

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 COMFORT SECURITIES LIMITED Address: 301, 3rd Floor, 'A' Wing, Hetal Arch, Opp. Natraj Market, S.V. Road, Malad (West), Mumbai, Maharashtra, India, 400064 Telephone Number: +91 - 8108486841 Email ID: merchantbanking@comfortsecurities.co.in Investors Grievance Id: merchantbanking@comfortsecurities.co.in Website: www.comfortsecurities.co.in Contact Person: Mr. Alok Prasad CIN: U67120MH2002PLC136562 SEBI Registration Number: INM000011328	 BIGSHARE SERVICES PRIVATE LIMITED Address: S6-2, 6th Floor, Pinnacle Business Park, Andheri (East), Mumbai - 400093, Maharashtra, India. Telephone Number: 022 6263 8200 Email ID: ipo@bigshareonline.com Investors Grievance Id: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Babu Raphael C. CIN: U99999MH1994PTC076534 SEBI Registration Number: INR000001385	 SOBO FILMS HOLDING LIMITED Sakshi Saxena Address: 713, 7th Floor, Crystal Paradise Mall, Dattaji Salvi Road, Off Veera Desai Road, Andheri (West), Mumbai- 400053, Maharashtra, India; Contact no.: +91-9892950013 Email: compliance@sobofilms.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus.

On behalf of SOBO FILMS HOLDING LIMITED
SD/-
SAKSHI SAXENA
Company Secretary and Compliance Officer

Date: September 30, 2025
Place: Mumbai

SOBO Films Holding Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed a draft prospectus dated September 30, 2025 with SME Platform of BSE Limited ("BSE SME"). The DP is available on website of BSE at www.bseindia.com, as well as on the websites of the LM at www.comfortsecurities.co.in, and Company at www.sobofilms.com as provided above. Any potential investor should note that investment in equity shares involves a high degree of risk. For details, please refer to the DP including the section "*Risk Factors*" beginning on page 34 of the DP. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws in the United States and may not be offered or sold within the United States except pursuant to an exemption from or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulations under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States. "

PUBLIC ANNOUNCEMENT

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE SME PLATFORM OF NSE (NSE EMERGE) IN COMPLIANCE WITH CHAPTER IX OF SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS").



(Please scan this QR Code to view the DRHP)



DASRA HEALTHCARE LIMITED

Our Company has been incorporated as a public limited company under the name and style of 'Dasra Healthcare Limited' under the Companies Act, 2013, pursuant to a Certificate of Incorporation dated March 27, 2024, issued by the Central Registration Centre. For further details of the name and registered office of our Company, see "*History and Certain Corporate Matters*" on page 160 of the Draft Red Herring Prospectus.

Registered Office: 3rd Floor, Krishna Hospital, Devriya Balaji Road, R C Vyas Colony, Bhilwara-311001 Rajasthan
Telephone: 01482-230356, 01482-230095, 01482-230096, 9166149166; **E-mail:** @dasrahealthcare.com; **Website:** www.dasrahealthcare.com
Contact Person: Palak Gupta, Company Secretary and Compliance Officer; **CIN:** U86100RJ2024PLC093525

OUR PROMOTERS: KAILASH CHANDRA KABRA, SANGEETA KABRA AND PRATEEK KABRA

INITIAL PUBLIC ISSUE OF UPTO 37,50,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF DASRA HEALTHCARE LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹[●] LAKHS ("THE ISSUE") OF WHICH UPTO [●] EQUITY SHARES AGGREGATING TO ₹[●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF UPTO [●] EQUITY SHARES AGGREGATING TO ₹[●] LAKHS (THE "NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE [●] % AND [●] % RESPECTIVELY OF THE POST ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein [●] (not more than 50 % of the Net Issue) shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "**QIB Portion**"), provided that our Company may, in consultation with the Book Running Lead Manager, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 314 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with pursuant to regulation 247 of the SEBI ICDR Regulation, 2018 along with F. No. SEBI/LAD-NRO/GN/2025/233 Notification dated March 03, 2025 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Amendment) Regulations, 2025 and applicability of corporate governance provisions under SEBI ICDR Regulations, 2015 on SME Companies for fulfilling all additional criteria, the DRHP filed with the SME Platform of National Stock Exchange of India Limited (NSE EMERGE) shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the NSE at www.nseindia.com, and the website of the Company at www.dasrahealthcare.com, and at the website of BRLM i.e. Mark Corporate Advisors Private Limited at https://www.markcorporateadvisors.com/. Our Company hereby invites the members of the public to give their comments to NSE EMERGE, to Company Secretary and Compliance Officer of our Company and for the BRLM at their respective addresses mentioned below. All comments must be received by NSE EMERGE and/or our Company and/or BRLM in relation to the issue on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with NSE EMERGE.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 31 of the Draft Red Herring Prospectus.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely based on such Red Herring Prospectus as there may be material changes in the RHP from the DRHP.

The Equity Shares, when offered, through the RHP, are proposed to be listed on SME Platform of National Stock Exchange of India Limited ("NSE EMERGE").

For details of the main objects of the Company as contained in its Memorandum of Association, see "*History and Certain Corporate Matters*" on page 160 of the DRHP. The liability of the members of the Company is limited. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them see "Capital Structure" on page 76 of the DRHP.

BOOK RUNNING LEAD MANAGER TO THE ISSUE



MARK CORPORATE ADVISORS PRIVATE LIMITED
CIN: U67190MH2008PTC181996
404/1, The Summit, Sant Janabai Road (Service Lane), Off Western Express Highway, Vile Parle (East), Mumbai 400 057
Tel No.: +91 22 2612 3207/08
E-Mail ID: smeipo@markcorporateadvisors.com
Investor Grievance Email: investor@grievance@markcorporateadvisors.com
Website: www.markcorporateadvisors.com/
Contact Person: Mr. Niraj Kothari
SEBI Registration No.: INM000012128

REGISTRAR TO THE ISSUE



BIGSHARE SERVICES PRIVATE LIMITED
CIN Number: U99999MH1994PTC076534
Office No. S6-2, 6th Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai-400093
Telephone: +91 22 62638200
E-Mail ID: ipo@bigshareonline.com
Investor grievance email: investor@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Asif Sayyed
SEBI Registration No.: INR00000138

COMPANY SECRETARY AND COMPLIANCE OFFICER

Palak Gupta
3rd Floor, Krishna Hospital, Devriya Balaji Road, R C Vyas Colony, Bhilwara-311001, Rajasthan, India
Tel. No.: +91 1482 230356/1482 230095
E-Mail ID: cs@dasrahealthcare.com
Website: www.dasrahealthcare.com

Investors can contact our Company Secretary and Compliance Officer, Book Running Lead Manager or Registrar to the Issue, in case of any pre issue or post issue related problems, such as non-receipt of letter of allotment, non-credit of allotted Equity shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For Dasra Healthcare Limited
On behalf of the Board of Directors
SD/-
Palak Gupta
Company Secretary and Compliance Officer

Place: Bhilwara
Date: October 01, 2025

DASRA HEALTHCARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the DRHP dated September 30, 2025, with NSE EMERGE. The DRHP is available on the website of NSE at www.nseindia.com and on the website of the BRLM, i.e. Mark Corporate Advisors Limited at www.markcorporateadvisors.com and the website of our Company at www.dasrahealthcare.com. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "*Risk Factors*" beginning on page 31 of the DRHP. Potential investors should not rely on the DRHP filed with NSE EMERGE for making any investment decision.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdictions where those offers and sales are made.

There will be no public offering of the Equity Shares in the United States.

FORTUNA + SHARK

When industry giants speak, everyone listens.

In-depth **Q&As** with market mavens — *every Monday* in Business Standard.

To book your copy, SMS **reachbs** to **57575** or email **order@bsmail.in**



Business Standard
Insight Out